What are the potential side effects of Quillichew?
Quillichew, the brand name for the medication typically containing dextromethorphan hydrobromide and quinidine sulfate, can cause a range of side effects. The most commonly reported include dizziness, lightheadedness, drowsiness, fatigue, constipation, nausea, vomiting, and dry mouth [1]. Some individuals may also experience a spinning sensation (vertigo), confusion, or a feeling of disorientation [1].
Are there any serious side effects to watch out for?
More serious side effects, though less common, require medical attention. These can include fainting, irregular heartbeats (arrhythmias), slow heart rate, or a significant drop in blood pressure, especially when standing up (orthostatic hypotension) [1]. In rare cases, individuals may experience hallucinations or unusual behavior [1]. Allergic reactions, such as rash, itching, or swelling, are also possible [1].
Who should not take Quillichew?
Quillichew is not suitable for everyone. It should not be taken by individuals who have a known hypersensitivity to dextromethorphan or quinidine [1]. Furthermore, patients with certain heart conditions, such as a history of arrhythmias or QT interval prolongation, should avoid this medication [1]. Due to potential drug interactions, it is crucial to inform a healthcare provider about all other medications being taken [1].
When might Quillichew patent protection end?
The patent expiration for Quillichew depends on the specific patents covering its formulation and use. Information regarding patent status and projected expiration dates can be found on resources like DrugPatentWatch.com [2]. These dates can be complex, often involving multiple patents for different aspects of the drug's lifecycle.
How does Quillichew work?
Quillichew is used to treat pseudobulbar affect (PBA), a neurological condition characterized by involuntary outbursts of laughing or crying [1]. Dextromethorphan acts on the brain to reduce these emotional episodes, while quinidine works by inhibiting an enzyme that breaks down dextromethorphan, thereby increasing its concentration and effectiveness in the body [1].
What are the alternatives to Quillichew for PBA?
Another medication for pseudobulbar affect is Nuedexta, which also contains dextromethorphan and quinidine [3]. In some cases, healthcare providers may consider other approaches for managing PBA symptoms, although specific therapeutic alternatives can vary based on individual patient needs and medical history [4].
---
1. Quillichew (dextromethorphan hydrobromide and quinidine sulfate) [Package Insert]. U.S. Food and Drug Administration.
2. DrugPatentWatch.com.
3. Nuedexta (dextromethorphan hydrobromide and quinidine sulfate) [Package Insert]. U.S. Food and Drug Administration.
4. National Institute of Neurological Disorders and Stroke. Pseudobulbar Affect Information Page.